- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05683340
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
April 9, 2024 updated by: Otsuka Pharmaceutical Co., Ltd.
A Placebo-controlled, Randomized, Multicenter, Double-blind, Parallel-group Trial to Confirm the Superiority of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Drug Information Center
- Phone Number: +81-3-6361-7314
Study Locations
-
-
-
Izumisano-shi, Japan
- Rinku General Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with inadequate response to statins or statin intolerance as defined below [Inadequate response to statins] Patients with hyper-LDL cholesterolemia who have been taking statins[and other lipid-modifying therapies(LMTs) if needed] and cannot achieve the lipid management goals of LDL-C [Statin intolerance] Patients with hyper-LDL cholesterolemia for whom safety problems have occurred while taking at least one type of statin, and who experienced resolution of the problems after discontinuation or dose reduction, and who cannot achieve the lipid management goals of LDL-C. Patients must be on the lowest or under the dosage of the approved dose of statin and/or on stable LMT(s).
- Patients with fasting TG levels of <400 mg/dL at screening
- Other protocol specific inclusion criteria may apply
Exclusion Criteria:
- Females who are pregnant or breast-feeding or who have a positive pregnancy test (urine) result at screening or baseline visits
- Patients with homozygous familial hypercholesterolemia (HoFH)
- Patients who currently have or who have had within the past 3 months prior to screening any cardiovascular diseases, or those who have developed any cardiovascular diseases during the screening or before baseline visit
- Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
- Patients with uncontrolled and serious hematologic or coagulation disorders or with hemoglobin of <10.0 g/dL at screening
- Patients with uncontrolled diabetes with HbA1c of ≥9% at screening
- Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × ULN at screening
Patients with liver disease or dysfunction, including:
- Positive serology for hepatitis B surface antigen (HBsAg) or a positive hepatitis C virus (HCV) antibody test at screening
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or total bilirubin of ≥2 × ULN at screening
- Patients with creatine kinase (CK) of >3 × ULN at screening
- Patients with a history or current renal dysfunction, nephritic syndrome, or nephritis, and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2 at screening
- Other protocol specific exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
placebo, tablet, once daily, for 12 weeks
|
Experimental: ETC-1002 180mg
|
180mg, tablet, once daily, for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in LDL-C from baseline at Week 12
Time Frame: Baseline, week12
|
Baseline, week12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Takehisa Matsumaru, Otsuka Pharmaceutical Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2023
Primary Completion (Actual)
February 20, 2024
Study Completion (Actual)
March 12, 2024
Study Registration Dates
First Submitted
January 4, 2023
First Submitted That Met QC Criteria
January 4, 2023
First Posted (Actual)
January 13, 2023
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 346-102-00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
IPD Sharing Time Frame
Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication.
There is no end date to the availability of the data.
IPD Sharing Access Criteria
"Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software.
Research requests should be directed to clinicaltransparency@Otsuka-us.com.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyper-low-density Lipoprotein (LDL) Cholesterolemia
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingHyper-low-density Lipoprotein (LDL) CholesterolemiaJapan
-
Jordan Collaborating Cardiology GroupThe Cardiovascular Academy Group of the JCS; The Jordan Cardiac Society (JCS); Istishari Hospital Department of Clinical ResearchTerminatedAtherosclerotic Cardiovascular Risk | Low-density-lipoprotein (LDL) CholesterolJordan
-
LIB Therapeutics LLCMedpace, Inc.Active, not recruitingCardiovascular Diseases | Hyper-LDL-cholesterolemiaUnited States
-
Nina HermansUniversity Hospital, AntwerpRecruitingLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaBelgium
-
S.LAB (SOLOWAYS)Center of New Medical Technologies; Triangel ScientificCompletedLDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II DiseaseRussian Federation
-
Syneos HealthSynerK Pharmatech (Suzhou) LimitedRecruitingElevated Low-Density Lipoprotein CholesterolAustralia
-
Novartis PharmaceuticalsCompletedHigh Levels of Low-density Lipoprotein CholesterolSwitzerland
-
InQpharm GroupCompletedBlood Pressure | Low Density Lipoprotein Cholesterol LevelGermany
-
Dhurakij Pundit UniversityNot yet recruitingDyslipidemias | Hypercholesterolemia | Hypertriglyceridemia | Postmenopausal Symptoms | Hyper-LDL-cholesterolemia | Hypo HDL Cholesterolaemia
-
University of Nevada, Las VegasUniversity of Oklahoma; Oklahoma State UniversityCompletedMetabolic Syndrome | Hyper-LDL-cholesterolemiaUnited States
Clinical Trials on 180mg of ETC-1002(bempedoic acid)
-
Otsuka Pharmaceutical Co., Ltd.CompletedHypercholesterolemiaJapan
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingHyper-low-density Lipoprotein (LDL) CholesterolemiaJapan
-
Esperion Therapeutics, Inc.Completed
-
Esperion Therapeutics, Inc.CompletedHypercholesterolemiaUnited States
-
Esperion Therapeutics, Inc.CompletedHypercholesterolemia | Atherosclerotic Cardiovascular DiseaseUnited States
-
Esperion Therapeutics, Inc.Completed
-
Esperion Therapeutics, Inc.CompletedHypercholesterolemia | Atherosclerotic Cardiovascular DiseasesUnited States, United Kingdom, Germany, Poland, Netherlands, Canada
-
Esperion Therapeutics, Inc.CompletedHypercholesterolemia | Atherosclerotic Cardiovascular Disease | Statin Adverse ReactionUnited States, Canada
-
Esperion Therapeutics, Inc.The Cleveland ClinicCompletedCardiovascular Diseases | Statin Adverse ReactionBelgium, Germany, United States, Austria, Estonia, Mexico, New Zealand, Spain, Russian Federation, Netherlands, Hungary, Australia, Denmark, South Africa, United Kingdom, Bulgaria, Argentina, Romania, Turkey, Croatia, Serbia, Canada, Lithuan... and more
-
Esperion Therapeutics, Inc.CompletedAtherosclerosis | Hypercholesterolemia | Statin Adverse ReactionUnited States